Pharmacoeconomic evaluation in Japanese pharmaceutical companies

Shunya Ikeda, Adam James Oliver, Naoki Ikegami

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


In Japan, since August 1992, materials derived from pharmacoeconomic evaluations have been accepted at the time of new drug price negotiation. Pharmaceutical companies generally consider the materials they submit to be private information. Moreover, it is unclear haw the government uses these materials in its policy decisions. In this paper, for the purpose of understanding the present status of pharmacoeconomic evaluation in Japanese pharmaceutical companies, the results from an investigative interview of selected employees at 22 pharmaceutical firms are outlined. An analysis of haw the submitted economic data are reflected in drug prices is provided. This analysis clarifies that in recent years pharmacoeconomic evaluations have been submitted for most new pharmaceutical products. A clear connection between the submitted economic materials and the issuing of premiums to innovative or useful products, however, was not found. It is concluded that there is an urgent need to construct a system in which the results of pharmacoeconomic evaluation can be appropriately used in government pricing decisions.

Original languageEnglish
Pages (from-to)169-174
Number of pages6
JournalDrug Information Journal
Issue number1
Publication statusPublished - 1998
Externally publishedYes


  • Japanese pharmaceutical companies
  • Pharmacoeconomic evaluation
  • Pharmacoeconomics
  • Pricing decision
  • Submission

ASJC Scopus subject areas

  • Pharmacology (nursing)
  • Drug guides
  • Public Health, Environmental and Occupational Health
  • Pharmacology (medical)


Dive into the research topics of 'Pharmacoeconomic evaluation in Japanese pharmaceutical companies'. Together they form a unique fingerprint.

Cite this